ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: TH-OR04

Roxadustat Is Not Associated with an Increased Risk of Neoplasm in Patients with CKD and Anemia

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Coyne, Daniel W., Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States
  • Fishbane, Steven, Northwell Health, Great Neck, New York, United States
  • Pergola, Pablo E., Renal Associates PA, San Antonio, Texas, United States
  • Leong, Robert, FibroGen Inc, San Francisco, California, United States
  • Zhong, Ming, FibroGen Inc, San Francisco, California, United States
  • Little, Dustin J., AstraZeneca, Gaithersburg, Maryland, United States
  • Yu, Kin-Hung Peony, FibroGen Inc, San Francisco, California, United States
Background

Roxadustat is a novel, orally bioavailable, small molecule that reversibly inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase enzymes and activates HIF and transcription of HIF-responsive genes, including for erythropoietin. Preclinical studies of roxadustat in multiple animal species did not demonstrate a carcinogenic signal. We report neoplasm-related adverse events (AEs) and serious adverse events (SAEs) from the roxadustat global phase 3 program.

Methods

Data from six pivotal studies were pooled: 3 compared roxadustat to placebo in patients with non–dialysis-dependent (NDD) CKD, and 3 compared roxadustat to epoetin alfa in patients with dialysis-dependent (DD) CKD. Patients were excluded from the studies if they had a history of malignancy, except for those determined to be cured or in remission for ≥5 years, curatively resected basal/squamous cell cancers, cervical cancer in situ, or resected colon polyps. AEs/SAEs reported during the treatment period +28 days and +7 days after the last dose of study drug in the NDD- and DD-CKD populations, respectively, were compared. Events were coded using the Medical Dictionary for Regulatory Activities, System Organ Class “Neoplasms benign, malignant and unspecified (incl cysts and polyps).”

Results

In the NDD population, 4270 patients were randomized (roxadustat=2386, placebo=1884), corresponding to 3870.7 and 2323.2 patient-exposure years (PEY), respectively. Neoplasm-related AE rates were 2.5/100 PEY in both the roxadustat and placebo groups. Neoplasm-related SAE rates were 1.1/100 PEY and 1.3/100 PEY in the roxadustat and placebo groups. In the DD population, 3880 patients were randomized (roxadustat=1940, epoetin alfa=1940), corresponding to 3315.3 and 3743.6 PEY, respectively. Neoplasm-related AE rates were 2.7/100 PEY and 2.3/100 PEY in the roxadustat and epoetin alfa groups. Neoplasm-related SAE rates were 1.1/100 PEY and 1.2/100 PEY. In both the NDD- and DD-CKD populations, there were no between–treatment-group differences in the organ types of neoplasms.

Conclusion

There were no clinically meaningful between–treatment-group differences in neoplasm-related AE and SAE rates in the roxadustat phase 3 clinical trials.

Funding

  • Commercial Support – Fibrogen, Inc.; AstraZeneca plc; Astellas Pharma Inc.